{"id":"W2167290534","doi":"10.1158/1078-0432.ccr-06-1432","title":"Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Melanoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Pharmacokinetics; Adverse effect; Cohort; Progressive disease; Gastroenterology; Combination therapy; Chemotherapy; Hepatocellular carcinoma; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004326909,0.0002159268,0.0008208904,0.0005670415,0.0000517699,0.00002121062,0.000165201,0.0001201636,0.0001897782],"category_scores_gemma":[0.0004606088,0.0001194335,0.00006029137,0.001147738,0.0004300712,0.0001109025,0.00009271737,0.0007185707,0.000004367644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004399402,"about_ca_system_score_gemma":0.001262499,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00223119,"about_ca_topic_score_gemma":0.005312554,"domain_scores_codex":[0.995727,0.0005762405,0.001039994,0.0005950871,0.001380342,0.0006813496],"domain_scores_gemma":[0.9968981,0.001634529,0.0002033163,0.0004243021,0.0004967861,0.0003430356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5838726,0.009970871,0.3952166,0.0003023303,0.00005906718,0.00117575,0.0002213902,0.000004359089,0.0001903062,0.00001538405,0.000093132,0.008878217],"study_design_scores_gemma":[0.4029835,0.0966681,0.4890308,0.0004362253,0.0001034295,0.000008561787,0.0002750634,0.00008408753,0.0100938,0.00003061999,0.0001159025,0.0001699531],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958482,0.0002694397,0.00002334636,0.0002078464,0.00005586932,0.003042484,0.00002289133,0.000008160046,0.0005218115],"genre_scores_gemma":[0.9981576,0.00007709201,0.0005237566,0.00003494964,0.0000640614,0.0001982684,0.00004065155,0.00003877958,0.0008648628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1808891,"threshold_uncertainty_score":0.4870355,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1713359032877744,"score_gpt":0.4647006839402991,"score_spread":0.2933647806525246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}